Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) was upgraded by equities researchers at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued on Thursday, Marketbeat.com reports. The firm presently has a $119.00 target price on the stock. Cantor Fitzgerald‘s target price points to a potential upside of 67.90% from […]